Each filer's latest filing for G3855L106 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Lynx1 Capital Management LP
13G/A
|
19.3% |
8/14/2026
Event 6/30/2026
|
||
| Lynx1 Capital Management LP | 19.3% | |||
| Weston Nichols | 19.3% | |||
|
Biotechnology Value Fund L P
13G/A
|
12.6% |
11/16/2026
Event 9/30/2026
|
||
| Biotechnology Value Fund L P | 6.6% | |||
| BVF I GP LLC | 6.6% | |||
| Biotechnology Value Fund II LP | 5.1% | |||
| BVF II GP LLC | 5.1% | |||
| Biotechnology Value Trading Fund OS LP | 0.9% | |||
| BVF Partners OS Ltd. | 0.9% | |||
| BVF GP Holdings LLC | 11.7% | |||
| BVF Partners L P/IL | 12.6% | |||
| BVF Inc/IL | 12.6% | |||
| Lampert Mark N | 12.6% | |||
|
FMR LLC
13G/A
|
9.4% |
11/5/2026
Event 9/30/2026
|
||
| FMR LLC | 9.4% | |||
| Abigail P. Johnson | 9.4% | |||
|
RTW Investments, LP
13G/A
|
8.9% |
5/15/2025
Event 3/31/2025
|
||
| RTW Investments, LP | 8.9% | |||
| Roderick Wong, M.D. | 8.9% | |||
|
RA Capital Management, L.P.
13G/A
|
5.3% |
11/16/2026
Event 9/30/2026
|
||
| RA Capital Management, L.P. | 5.3% | |||
| Peter Kolchinsky | 5.3% | |||
| Rajeev Shah | 5.3% | |||
| RA Capital Healthcare Fund, L.P. | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
| Terwey Theis H 13G/A | 2.9% |
11/14/2025
Event 9/30/2025
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 80 | 50.8 M | $1.19B |
| 2026 Q2 | 64 | 51.5 M | $1.38B |
| 2026 Q1 | 55 | 47.6 M | $669M |
| 2025 Q4 | 53 | 46.6 M | $591M |
| 2025 Q3 | 48 | 44.5 M | $618M |
| 2025 Q2 | 39 | 43.6 M | $531M |
| 2025 Q1 | 37 | 42.6 M | $470M |
| 2024 Q4 | 33 | 30.7 M | $215M |
| 2024 Q3 | 29 | 30.5 M | $204M |
| 2024 Q2 | 30 | 30.4 M | $355M |
| 2024 Q1 | 33 | 29.6 M | $316M |
| 2023 Q4 | 36 | 29.6 M | $172M |
| 2023 Q3 | 30 | 29.0 M | $291M |
| 2023 Q2 | 35 | 29.6 M | $352M |
| 2023 Q1 | 30 | 29.7 M | $237M |
| 2022 Q4 | 33 | 30.9 M | $299M |
| 2022 Q3 | 35 | 31.6 M | $367M |
| 2022 Q2 | 36 | 32.6 M | $325M |
| 2022 Q1 | 34 | 32.1 M | $587M |
| 2021 Q4 | 31 | 30.0 M | $701M |
| 2021 Q3 | 31 | 28.5 M | $625M |
| 2021 Q2 | 35 | 27.6 M | $594M |